Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: a double-blind, randomized, placebo-controlled evaluation of two doses

Sotalol is a unique beta-adrenergic blocking agent with additional actions characteristic of Vaughn-Williams class III antiarrhythmic agents in experimental models. To test the efficacy of sotalol to suppress ventricular arrhythmias, a 6 week parallel, placebo-controlled out-patient study of two doses (320 and 640 mg/day, in two divided doses) was performed in four hospitals in 56 patients with chronic premature ventricular complexes at a frequency of 30/h or more (mean +/- SE, 528 +/- 60/h) on 48 hour ambulatory electrocardiographic recording. During a placebo week, no change occurred in arrhythmia frequency (532 +/- 76/h). Subsequent sotalol therapy significantly reduced median arrhythmia frequency in patients receiving both low (n = 19) and high (n = 18) doses compared with that in patients receiving placebo (by 77 and 83%, respectively, versus 6%; p less than 0.001). Twenty-two (59%) of 37 sotalol-treated patients, 11 in each group, reached the prospectively defined criterion of efficacy (greater than or equal to 75% arrhythmia reduction) versus 2 (11%) of 19 placebo control patients (p less than 0.001). Sotalol reduced the median frequency of couplets by 94% (p less than 0.0001) and that of runs by 89% (p less than 0.0007). The electrocardiographic effects of sotalol included reductions in heart rate (by 17 to 27%) and increases in the QTc (by 6 to 9%) and PR (by 6%) intervals. Ejection fraction was unchanged. The most common adverse side effect was fatigue, but drug discontinuation was required in only three patients taking 640 mg/day. No proarrhythmic events or biochemical abnormalities were observed. In summary, sotalol displays significant antiarrhythmic activity of moderately high degree with good tolerance in doses of both 320 and 640 mg/day. Its antiarrhythmic actions are distinguished from those reported for other beta-blockers by its effects on the QTc interval and its moderately high degree of antiarrhythmic activity.

This article has been cited by other articles:

				R. Sanjuan, M. Blasco, N. Carbonell, A. Jorda, J. Nunez, J. Martinez-Leon, and E. Otero Preoperative use of sotalol versus atenolol for atrial fibrillation after cardiac surgery Ann. Thorac. Surg., March 1, 2004; 77(3): 838 - 843. [Abstract] [Full Text] [PDF]

				P. Evrard, M. Gonzalez, J. Jamart, B. Malhomme, D. Blommaert, P. Eucher, and E. Installe Prophylaxis of supraventricular and ventricular arrhythmias after coronary artery bypass grafting with low-dose sotalol Ann. Thorac. Surg., July 1, 2000; 70(1): 151 - 156. [Abstract] [Full Text] [PDF]

				P. C. Deedwania Sotalol Is More Powerful Than Propranolol in Suppressing Complex Ventricular Arrhythmias Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 259 - 272. [Abstract] [PDF]

				C. Holubarsch, R. Schneider, B. Pieske, T. Ruf, G. Hasenfuss, G. Fraedrich, H. Posival, and H. Just Positive and Negative Inotropic Effects of DL-Sotalol and D-Sotalol in Failing and Nonfailing Human Myocardium Under Physiological Experimental Conditions Circulation, November 15, 1995; 92(10): 2904 - 2910. [Abstract] [Full Text]

				S. H. Hohnloser, T. Meinertz, P. Stubbs, H. J.G.M. Crijns, J.-J. Blanc, P. Rizzon, and B. Cheuvart Efficacy and Safety of d-Sotalol, a Pure Class III Antiarrhythmic Compound, in Patients With Symptomatic Complex Ventricular Ectopy : Results of a Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Finding Study Circulation, September 15, 1995; 92(6): 1517 - 1525. [Abstract] [Full Text]